Login
Super Investors ACUTA CAPITAL PARTNERS, LLC
AC

ACUTA CAPITAL PARTNERS, LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$132M
Positions
35
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (48 quarters reported)

$612M $71.6M
Q4 14 Q2 17 Q4 19 Q2 22 Q4 24 Q3 26

$148M in Q4 2014 → $132M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
PP Praxis Precision Medicines I 18.6% Added 1.7% 84,193 $24.5M
Whitehawk Therapeutics Inc 13.4% Unchanged 4,685,912 $17.6M
Tango Therapeutics Inc 7.8% Added 4.8% 409,529 $10.2M
4M 4d Molecular Therapeutics In 5.8% Added 5.4% 535,109 $7.66M
AS Argen Se - ADR 4.0% Added 18% 5,558 $5.33M
Arrivent Biopharma Inc 3.9% Trimmed 22% 170,893 $5.17M
Surrozen Inc 3.7% Trimmed 12% 152,541 $4.91M
V Vogenx Inc 3.7% New 213,186 $4.86M
Bright Minds Biosciences Inc 3.5% Added 0.4% 93,152 $4.64M
Ocular Therapeutix Inc 3.3% Added 7.9% 574,543 $4.41M
Silence Therapeutics PLC 3.3% New 393,583 $4.3M
Taysha Gene Therapies Inc 2.6% Added 23% 691,843 $3.37M
Avalyn Pharma Inc 2.5% Trimmed 0.2% 114,749 $3.27M
Avalo Therapeutics Inc 2.2% Unchanged 186,308 $2.86M
Moonlake Immunotherapeutics 1.9% Added 0.4% 216,568 $2.53M
Opus Genetics Inc 1.9% New 514,110 $2.49M
Minerva Neurosciences 1.9% Added 2.8% 729,500 $2.44M
Lb Pharmaceuticals Inc 1.5% Added 82% 52,718 $2.02M
Acadia Pharmaceuticals Inc Call 1.5% New 1,000 $2.02M
Artiva Biotherapeutics Inc 1.4% Unchanged 260,416 $1.85M
Amylyx Pharmaceuticals Inc 1.4% Trimmed 63% 62,956 $1.83M
Revolution Medicines Inc 1.3% New 8,237 $1.69M
Irulya Therapeutics Inc 1.2% New 52,918 $1.64M
Roivant Sciences Ltd 1.2% New 41,535 $1.52M
Design Therapeutics Inc 1.1% Trimmed 59% 115,392 $1.45M
United Therapeutics Corp 0.9% Added 0.7% 2,240 $1.21M
CT Contineum Therapeutics Inc-a 0.9% Added 42% 89,826 $1.21M
Oric Pharmaceuticals Inc 0.9% New 87,918 $1.18M
Erasca Inc 0.8% Trimmed 75% 67,541 $990K
An2 Therapeutics Inc 0.6% New 142,051 $756K
Adial Pharmaceuticals Inc 0.4% New 129,982 $521K
Sutro Biopharma Inc 0.3% Trimmed 91% 25,290 $407K
Equillium Inc 0.2% New 183,000 $297K
Compass Therapeutics Inc 0.2% Trimmed 58% 251,001 $261K
Stoke Therapeutics Inc 0.1% New 5,771 $150K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
V Vogenx Inc New +213,186 +$4.86M 3.7%
Silence Therapeutics PLC New +393,583 +$4.3M 3.3%
Sutro Biopharma Inc Trimmed −244,961 −$3.95M 0.3%
Amylyx Pharmaceuticals Inc Trimmed −105,159 −$3.06M 1.4%
Erasca Inc Trimmed −197,658 −$2.9M 0.8%
Opus Genetics Inc New +514,110 +$2.49M 1.9%
Design Therapeutics Inc Trimmed −167,172 −$2.1M 1.1%
Acadia Pharmaceuticals Inc New +1,000 +$2.02M 1.5%
Revolution Medicines Inc New +8,237 +$1.69M 1.3%
Irulya Therapeutics Inc New +52,918 +$1.64M 1.2%

Showing the 10 largest of 32 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Terns Pharmaceuticals Inc Exited −495,772 −$26.1M —
Arrivent Biopharma Inc New +218,694 +$7.6M 5.3%
4d Molecular Therapeutics Inc New +507,801 +$6.75M 4.7%
Whitehawk Therapeutics Inc Added +1,275,510 +$5.84M 15.0%
Avalyn Pharma Inc New +115,000 +$3.79M 2.6%
Oculis Holding Ag Exited −98,339 −$2.61M —
Revolution Medicines Inc Exited −26,069 −$2.54M —
Artiva Biotherapeutics Inc New +260,416 +$2.53M 1.8%
Avalo Therapeutics Inc Added +125,500 +$2.32M 2.4%
4d Molecular Therapeutics Inc Exited −242,255 −$2.26M —

Showing the 10 largest of 29 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Cidara Therapeutics Inc Exited −89,145 −$19.7M —
Terns Pharmaceuticals Inc Trimmed −141,323 −$7.45M 18.4%
Erasca Inc New +354,575 +$5.74M 4.0%
Sutro Biopharma Inc Added +201,974 +$5.03M 4.7%
Jazz Pharmaceuticals PLC Exited −29,008 −$4.93M —
Insmed Inc Exited −25,878 −$4.5M —
Ocular Therapeutix Inc Trimmed −460,887 −$3.9M 3.5%
Tango Therapeutics Inc Added +159,099 +$3.33M 6.5%
Amylyx Pharmaceuticals Inc Trimmed −182,191 −$2.53M 1.5%
Moonlake Immunotherapeutics Added +132,480 +$2.47M 2.5%

Showing the 10 largest of 34 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Tourmaline Bio Inc Exited −268,451 −$12.8M —
Cidara Therapeutics Inc Trimmed −52,384 −$11.6M 13.4%
PP Praxis Precision Medicines I Added +33,285 +$9.81M 16.6%
Terns Pharmaceuticals Inc Added +134,298 +$5.43M 17.5%
Minerva Neurosciences New +709,500 +$2.85M 1.9%
Tango Therapeutics Inc New +282,732 +$2.51M 1.7%
Insmed Inc Trimmed −12,714 −$2.21M 3.1%
AP Ascendis Pha-adr Exited −9,792 −$1.95M —
Krystal Biotech Inc Exited −10,573 −$1.87M —
Cogent Biosciences Inc Exited −102,907 −$1.48M —

Showing the 10 largest of 22 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Soleno Therapeutics Inc Exited −63,436 −$5.31M —
Amylyx Pharmaceuticals Inc New +333,258 +$4.53M 4.7%
Cidara Therapeutics Inc Trimmed −38,040 −$3.64M 14.0%
Compass Therapeutics Inc New +840,090 +$2.94M 3.0%
Trevi Therapeutics Inc Exited −493,735 −$2.7M —
AP Ascendis Pha-adr Trimmed −12,784 −$2.54M 2.0%
Bright Minds Biosciences Inc Added +36,401 +$2.21M 5.3%
Revolution Medicines Inc Trimmed −47,282 −$2.21M 0.4%
Helix Acquisition Corp Ii Exited −187,257 −$1.99M —
Krystal Biotech Inc New +10,573 +$1.87M 1.9%

Showing the 10 largest of 34 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Insmed Inc Trimmed −69,004 −$6.94M 5.2%
Enliven Therapeutics Inc Exited −265,269 −$5.22M —
Cidara Therapeutics Inc Added +53,861 +$2.62M 12.2%
Tourmaline Bio Inc Trimmed −143,200 −$2.29M 6.3%
Merck & Co Exited −22,994 −$2.06M —
Ocular Therapeutix Inc Trimmed −204,784 −$1.9M 13.1%
Edgewise Therapeutics Inc Exited −85,454 −$1.88M —
MB Mereo Biopharma Group Pl-adr Exited −791,815 −$1.78M —
Jazz Pharmaceuticals PLC Added +16,708 +$1.77M 3.9%
Trevi Therapeutics Inc Trimmed −292,226 −$1.6M 3.8%

Showing the 10 largest of 33 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
CP Crinetics Pharmaceuticals In Exited −122,900 −$6.28M —
Soleno Therapeutics Inc New +67,136 +$4.8M 5.6%
Vaxcyte Inc Exited −45,000 −$3.68M —
Whitehawk Therapeutics Inc Added +1,561,000 +$2.78M 7.0%
Oculis Holding Ag New +125,000 +$2.38M 2.8%
Merck & Co New +22,994 +$2.06M 2.4%
Surrozen Inc New +170,000 +$1.98M 2.3%
Mersana Therapeutics Inc Exited −1,120,500 −$1.6M —
Revolution Medicines Inc Trimmed −45,038 −$1.59M 2.7%
Cidara Therapeutics Inc Added +71,235 +$1.53M 3.1%

Showing the 10 largest of 44 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Vaxcyte Inc Trimmed −90,400 −$7.4M 3.7%
Arcellx Inc Trimmed −51,357 −$3.94M 0.8%
KO Kura Oncology Inc. Common Stock Exited −197,000 −$3.85M —
Bright Minds Biosciences Inc New +69,124 +$2.49M 2.5%
Compass Pathways PLC Exited −386,500 −$2.43M —
Taysha Gene Therapies Inc Trimmed −1,234,748 −$2.14M 1.5%
Trevi Therapeutics Inc Added +481,458 +$1.98M 3.2%
Acelyrin Inc Exited −364,000 −$1.79M —
MB Mereo Biopharma Group Pl-adr Trimmed −481,392 −$1.68M 2.7%
Dyne Therapeutics Inc Exited −46,200 −$1.66M —

Showing the 10 largest of 45 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support